fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

ACC 2014 Report: ACE Inhibitors better than ARBs in CV patients with diabetes

Written by | 23 Apr 2014 | All Medical News

Report from the ACC Annual Scientific Meeting, 29 – 31 March 2014 in Washington.   Angiotensin-converting-enzyme (ACE) inhibitors are associated with reduced mortality and cardiovascular events in patients with diabetes, while angiotensin-receptor blockers (ARBs) have little effect, according to a meta-analysis in JAMA Internal Medicine.

Researchers assessed the results of 35 randomized, controlled studies comprising some 56,000 patients. Participants had been randomized to either the active group (ACE inhibitors or ARBs) or a comparator group (placebo, no treatment, or other antihypertensive drugs).

Use of ACE inhibitors was associated with a 13% to 17% risk reduction in all-cause mortality, cardiovascular mortality, and major cardiovascular events. ARB users did not see a similar benefit. However, ARBs were associated with a 30% risk reduction in heart failure.

The researchers showed that  Angiotensin-converting enzyme inhibitors reduced all-cause mortality, CV mortality, and major CV events in patients with DM, whereas ARBs had no benefits on these outcomes.

The authors conclude that ACE inhibitors “should be considered as first-line therapy to limit the excess mortality and morbidity in this population.”

JAMA Internal Medicine article (Free abstract)

Reference: JAMA Intern Med. Published online March 31, 2014. doi:10.1001/jamainternmed.2014.348

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.